Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lucid Diagnostics (LUCD) Cash from Financing Activities (2021 - 2025)

Lucid Diagnostics (LUCD) has disclosed Cash from Financing Activities for 5 consecutive years, with $27.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash from Financing Activities rose 28761.7% year-over-year to $27.1 million, compared with a TTM value of $77.0 million through Sep 2025, up 118.52%, and an annual FY2024 reading of $48.2 million, up 63.77% over the prior year.
  • Cash from Financing Activities was $27.1 million for Q3 2025 at Lucid Diagnostics, up from $16.5 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $64.3 million in Q4 2021 and bottomed at $1000.0 in Q4 2022.
  • Average Cash from Financing Activities over 5 years is $12.4 million, with a median of $5.0 million recorded in 2023.
  • The sharpest move saw Cash from Financing Activities plummeted 100.0% in 2022, then skyrocketed 499900.0% in 2023.
  • Year by year, Cash from Financing Activities stood at $64.3 million in 2021, then tumbled by 100.0% to $1000.0 in 2022, then surged by 499900.0% to $5.0 million in 2023, then soared by 259.98% to $18.0 million in 2024, then soared by 50.73% to $27.1 million in 2025.
  • Business Quant data shows Cash from Financing Activities for LUCD at $27.1 million in Q3 2025, $16.5 million in Q2 2025, and $15.4 million in Q1 2025.